Los Angeles-based cannabis biotech Vitality Biopharma, Inc. (OTCQB: VBIO) filed national patent applications in the US and Canada in October for cannabidiol (CBD) compounds effective in neural repair using remyelination and is still waiting to hear results.
Cannabidiol (CBD), a non-intoxicating cannabinoid the FDA already approved to treat epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair.
The patent rights are based on work performed by the Myelin Repair Foundation (MRF), which assigned these rights to Vitality in 2016. The results were published in BMC Neuroscience. Researchers discovered several drugs useful in effecting remyelination, a form of nervous system regeneration critical to restoring lost function from multiple sclerosis. Emerging research also points to a role in addiction, stroke, and schizophrenia.
Vitality Biopharma is working with cannabinoids to discover treatments for neurological and inflammatory disorders. For more information, visit: www.vitality.bio or follow it on Facebook, Twitter and LinkedIn.
Risk of Prosecution for Marijuana-Related Companies. If you are considering investing in a company that is connected to the marijuana industry, be aware that marijuana-related companies may be at risk of federal, and perhaps state, criminal prosecution. The Department of Treasury recently issued guidance noting: “[T]he Controlled Substances Act (“CSA”) makes it illegal under federal law to manufacture, distribute, or dispense marijuana. Many states impose and enforce similar prohibitions. Notwithstanding the federal ban, as of the date of this guidance, 20 states and the District of Columbia have legalized certain marijuana-related activity.”